Circulating Interleukin-22 Is a Biomarker for Newly Diagnosed Type 2 Diabetes Mellitus and Associated with Hypoglycemic Effect of Sitagliptin
Serum IL-22 is a significant independent risk factor for T2DM, implying that circulating IL-22 may be a predictive biomarker and therapeutic target for T2DM.
Authors
- Yujie Feng (ORCID: https://orcid.org/0000-0002-0686-3937)
- Yuxi Xiao
- Hongting Zheng (ORCID: https://orcid.org/0000-0002-6930-0103)
- Xiaoyu Liao (ORCID: https://orcid.org/0000-0001-9851-3848)
- Yuan Dong (ORCID: https://orcid.org/0000-0001-8742-3492)
- Pinghui Sun (ORCID: https://orcid.org/0009-0005-1029-1678)
Institutions
- Army Medical University (CN)
Publication Details
- Journal
- Diabetes Metabolic Syndrome and Obesity
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/dmso.s509866
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.59